Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Volume Increase – What’s Next?

Posted by Jessica Moore on Jul 17th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) saw an uptick in trading volume on Friday . Approximately 351,670 shares changed hands during trading, an increase of 151% from the previous session’s volume of 140,259 shares.The stock last traded at $12.0870 and had previously closed at $12.07.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, June 23rd. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Check Out Our Latest Analysis on Fresenius SE & Co.

Fresenius SE & Co. Price Performance

The firm has a market capitalization of $27.31 billion, a P/E ratio of 16.16 and a beta of 0.63. The stock’s fifty day simple moving average is $11.42 and its 200 day simple moving average is $12.94. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.27 and a quick ratio of 0.98.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.09% and a net margin of 6.55%.The firm had revenue of $6.75 billion during the quarter, compared to analysts’ expectations of $6.79 billion. On average, equities research analysts predict that Fresenius SE & Co. will post 1.03 EPS for the current year.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.